In nonalcoholic steatohepatitis (NASH) models, pirfenidone's anti‐inflammatory effect, which inhibits TNF‐alpha, has been shown to decrease the activation of fibrotic pathways and hepatocyte apoptosis by reducing the activation of caspases 3 and 8 and returning hepatic stellate cells to a quiescent state.72 Here, CASP3 is linked to metabolic dysfunction-associated steatohepatitis.